Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference & Others

Rhea-AI Summary

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced that CEO Dr. Milton Werner will present at two upcoming virtual healthcare conferences. The first is the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:30 PM ET, followed by the LD Micro Virtual Invitational XI on June 10, 2021, at 11:30 AM ET. Dr. Werner will discuss the clinical pharmacokinetics and adverse event profile of IkT-148009, the company's leading treatment for Parkinson's disease. Webcasts will be available for on-demand viewing on the company's website for 30 days after each event.

ATLANTA, May 25, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced that Dr. Milton Werner, Ph.D., Chief Executive Officer of Inhibikase, will present at the Jefferies Virtual Healthcare Conference:

Jefferies Virtual Healthcare Conference
Date: Tuesday, June 1, 2021
Time: 3:30pm ET

The Company also announced a presentation by Dr. Werner at the LD Micro Virtual Invitational XI:

LD Micro Virtual Invitational XI
Date: Thursday, June 10, 2021
Time: 11:30am ET

Dr. Werner will present and discuss the clinical pharmacokinetics and adverse event profile of IkT-148009, the Company's lead asset being developed for the treatment of Parkinson's disease in the brain and gastrointestinal tract.

Webcasts of the presentations will be available for on-demand viewing under "News & Events" in the Investors section of the Company's website, www.inhibikase.com. An archived replay of the webcasts will be available for approximately 30 days following each event.

About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. Inhibikase is currently performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. The Company is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-upcoming-jefferies-virtual-healthcare-conference--others-301298468.html

SOURCE Inhibikase Therapeutics, Inc.

FAQ

What will Inhibikase present at the Jefferies Virtual Healthcare Conference?

Inhibikase will present information about its lead asset, IkT-148009, focusing on its clinical pharmacokinetics and adverse event profile.

When is Inhibikase's presentation at the Jefferies Conference?

The presentation at the Jefferies Virtual Healthcare Conference is scheduled for June 1, 2021, at 3:30 PM ET.

What is the date and time of the LD Micro Virtual Invitational XI?

The LD Micro Virtual Invitational XI will take place on June 10, 2021, at 11:30 AM ET.

Where can I view the presentations from Inhibikase?

Webcasts of the presentations will be available for on-demand viewing in the Investors section of Inhibikase's website for approximately 30 days after each event.

What is IkT-148009 developed by Inhibikase for?

IkT-148009 is being developed for the treatment of Parkinson's disease, targeting both the brain and gastrointestinal tract.